FDA Action Affects Products Marketed by Hi-Tech Pharmacal's ECR Pharmaceuticals Subsidiary

Hi-Tech Pharmacal Co. HITK, a specialty pharmaceuticals company, announced today that the US Food and Drug Administration has indicated, in its MedWatch publication, that the Agency intends to remove approximately 500 currently marketed cough/cold and allergy related products. Three of these are currently marketed by ECR Pharmaceuticals, a wholly owned subsidiary of Hi-Tech Pharmacal, Co., Inc.

The affected products are Lodrane 24 capsules, Lodrane 24 D capsules, Lodrane 12 D tablets.